Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy PerkinElmer, Inc.,a global leader committed to innovating for a healthier world, today announced that
Better Outfitted and Screened Viral Vectors Are Safer and More Effective Better Outfitted and Screened Viral Vectors Are Safer and More Effective
Adeno-associated virus (AAV) vectors are the leading vectors for gene delivery. Two AAV-based gene therapies have been approved by the U.S. Food and Drug administration, and dozens more are in clinical trials. However, AAV vectors pose challenges including costly manufacture, high percentages of empty capsids, and safety issues associated with high-dose regimens. To address this last challenge, developers are working to improve the impact of each AAV particle so that fewer particles will be required. [Dr. Microbe/Getty Images]
(Sanofi)
French Big Pharma Sanofi is teaming up with Germany’s Sirion Biotech for its viral-vector-based gene delivery tech.
The pair will work together on developing improved tissue-selective adeno-associated virus (AAV) vectors to tee up better gene therapy treatments. Targets have not yet been specifically mentioned, simply for “disorders affecting major human organs.” Financials of the deal were not made public.
This comes two years after Sirion penned a similar pact with Denali Therapeutics, with other partners including Acucela and Orchard Therapeutics.
Sanofi will work with Sirion and the German company’s partner at Heidelberg University Hospital, Dirk Grimm, to develop new and modified AAV capsids. The overall goal is to make safer, better gene therapies.
Posted on 192
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases. Sanofi, together with SIRION Biotech and Prof. Dirk Grimm, a world-renowned and pioneering scientist in the field of AAV biology and application working at Heidelberg University Hospital (Germany), will combine their proprietary technology platforms to create a next generation of AAV vectors. The goal of this collaboration is to develop new and modified AAV capsids that exhibit a safe prod